



Brussels, **XXX**
SANTE/10220/2022 ANNEX feedback
(POOL/E5/2022/10220/10220-EN
ANNEX feedback.docx)
[...] (2022) **XXX** draft

ANNEX

ANNEX

to the

COMMISSION IMPLEMENTING REGULATION (EU) .../...

**designating antimicrobials or groups of antimicrobials reserved for treatment of certain
infections in humans, in accordance with Regulation (EU) 2019/6 of the European
Parliament and of the Council**

ANNEX

Antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans

- (1) Antibiotics
 - (a) Carboxypenicillins
 - (b) Ureidopenicillins
 - (c) Ceftobiprole
 - (d) Ceftaroline
 - (e) Combinations of cephalosporins with beta-lactamase inhibitors
 - (f) Siderophore cephalosporins
 - (g) Carbapenems
 - (h) Penems
 - (i) Monobactams
 - (j) Phosphonic acid derivatives
 - (k) Glycopeptides
 - (l) Lipopeptides
 - (m) Oxazolidinones
 - (n) Macrocycles
 - (o) Plazomicin
 - (p) Glycylcyclines
 - (q) Eravacycline
 - (r) Omadacycline
- (2) Antivirals
 - (a) Amantadine
 - (b) Baloxavir marboxil
 - (c) Celgosivir
 - (d) Favipiravir
 - (e) Galidesivir
 - (f) Lactimidomycin
 - (g) Laninamivir
 - (h) Methisazone/metisazone
 - (i) Molnupiravir
 - (j) Nitazoxanide
 - (k) Oseltamivir
 - (l) Peramivir
 - (m) Ribavirin

- (n) Rimantadine
 - (o) Tizoxanide
 - (p) Triazavirin
 - (q) Umifenovir
 - (r) Zanamivir
- (3) Antiprotozoals
- (a) Nitazoxanide